Ramy Riad: Advancing Plasma-Derived Therapies Through Partnership
Ramy Riad, President of Plasma-Derived Therapies Business Unit at Takeda, shared a post on LinkedIn:
“Wrapping up a productive first day at IPPC 2026, hosted by Plasma Protein Therapeutics Association (PPTA), with a real sense of momentum.
This year’s theme — ‘Resilience, Reach and Responsibility’ — perfectly captures the leadership imperative facing our industry.
No single organization can sustain the plasma ecosystem alone.
It requires long‑term partnerships and shared responsibility across the value chain.
Today’s conversations reinforced how essential collaboration is to protect access for the patients who depend on plasma-derived therapies.
Looking forward to the sessions ahead and to connecting with fellow leaders shaping the future of plasma.”

Stay updated with Hemostasis Today.
-
Nov 16, 2026, 15:35Jim Hoffman: Could Blood Purification Change the Fight Against Cancer?
-
Nov 16, 2026, 15:16How Do Artificial Hearts Affect Platelet Function? – Platelets Journal
-
Nov 16, 2026, 15:10Assessing Coagulation Activation in DOAC – Treated Patients – JTH
-
Nov 16, 2026, 15:00Davide Antonio Mei: Should Anticoagulation Continue After AF Ablation?
-
Nov 16, 2026, 14:55Danielle Boyle: Beyond Platelet Counts – Why Patient Stories Matter
-
Nov 16, 2026, 14:28Jan Sloves: The Future of Vascular Ultrasound
-
Nov 16, 2026, 13:49Bahman Rasouli: A Rare Vascular Manifestation of Recurrent Papillary Thyroid Carcinoma
-
Nov 16, 2026, 13:28Muhammad Danyal: Platelet Patterns in Hepatitis B and C
-
Nov 16, 2026, 12:52Frank Nocken: Alzheimer’s Research Expands Beyond Amyloid-Based Treatments